

## Press Release

Zug, 1 June 2012

### **Nabriva Therapeutics signs Agreement for Collaboration and Option for Sale of the Company**

Nabriva Therapeutics, a portfolio company of HBM BioVentures, today announced the signing of a collaboration agreement with Forest Laboratories (NYSE: FRX) for the development of BC-3781, a novel class of antibiotics. Under the terms of the agreement, Forest pays USD 25 million to Nabriva and will over the next 12 months fund and conduct in collaboration with Nabriva certain development activities related to BC-3781. During the 12-month-period, Forest has the exclusive right to acquire Nabriva.

HBM BioVentures has invested EUR 12,9 Millionen in Nabriva and owns around 13% of the company. The value of the investment will not be adjusted. Further details on the transaction will only be disclosed after the exercise of the purchase option.

For further information, please contact Dr Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, [andreas.wicki@hbmbioventures.com](mailto:andreas.wicki@hbmbioventures.com).

#### **About Nabriva Therapeutics**

Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics for the treatment of serious infections caused by resistant pathogens. Nabriva's lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia. Nabriva Therapeutics is located in Vienna, Austria. Further information can be found on the company's website [www.nabriva.com](http://www.nabriva.com).

#### **Profile of HBM BioVentures AG**

HBM BioVentures invests in the healthcare sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of

# NOT FOR DISTRIBUTION IN USA, CANADA, JAPAN OR AUSTRALIA

**HBM BioVentures**

investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM BioVentures an interesting alternative to investing in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

## Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

**HBM BioVentures Ltd**

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | [info@hbmbioventures.com](mailto:info@hbmbioventures.com)  
[www.hbmbioventures.com](http://www.hbmbioventures.com)